Posts by this author

First-of-its-kind AI-based Diagnostics Solutions Approved in Europe

   914
First-of-its-kind AI-based Diagnostics Solutions Approved in Europe

According to the World Health Organisation, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 - nearly every 6th death worldwide happens because of this disease. Among all cancer cases, the top 3 types of cancer by incidence were breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases). With the drastic lifespan increase over the last semi-centenary, more and more people will be diagnosed with cancer. Based on 2015-2017 data National Cancer Institute of the United States concluded that 39.5% of men and women will become oncology patients at some point of their lives. And this number will only increase as NIH expects a trifold rise of cancer related deaths in 2040 compared to 2020.These appalling predictions leave no other choice than to address this problem, and  major biotech companies and renowned research institutions all over the world are striving to offer solutions to this challenge for more than a century.  

Major VC Rounds For AI Companies in Drug Discovery and Biotech in 2022

   1152
Major VC Rounds For AI Companies in Drug Discovery and Biotech in 2022

Despite the economic situation and political climate in 2022, such fields as drug discovery and biotech keep evolving and bringing vital solutions to challenges of the time drawing the attention of venture capitalists (VCs). In this piece let's focus specifically on artificial intelligence (AI)-driven biotech and drug discovery companies which managed to attract investors and raise notable rounds in 2022.

The Rise of Synthetic Biology Platforms

   571
The Rise of Synthetic Biology Platforms

Even though the term ‘synthetic biology’ remains foreign to an average person, the idea behind it is familiar to many. Nearly 3 decades ago Steven Spielberg released a famous sci-fi movie where a bunch of genetically modified creatures escapes the premises and starts terrorizing human beings. And while Hollywood scenarists use stories similar to this one from ‘Jurassic world’ to play on the audience’s nerves, major scientific advances in life sciences over the last 50 years provided researchers with technologies that could turn those scenarios into reality. 

So what is synthetic biology? Polish geneticist Waclaw Szybalski introduced this term to designate the engineering of natural biologic systems such as bacteria, yeasts and fungi, plants and animals to produce the desired products. A known example of synthetic biology application is rice modified to produce beta-carotene, a nutrient usually associated with carrots, to prevent child vitamin A deficiency in poor countries.

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

   462
9 Companies Using Artificial Intelligence to Fight Infectious Diseases

Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies the right to be the sole supplier of a new drug in a certain country to make such time and efforts investments justified. But if we are talking about a rapidly developing new plague, time resources at the disposal of the pharmaceutical industry appear to be scarce and new solutions to emerging challenges have to be found faster.  

AI-driven Anima Biotech Achieves Milestone with Takeda Illustrating Opportunities in Small Molecule mRNA Drugs Discovery

   734
AI-driven Anima Biotech Achieves Milestone with Takeda Illustrating Opportunities in Small Molecule mRNA Drugs Discovery

New Jersey-based Anima Biotech, a leader in the discovery of small molecule mRNA drugs and their mechanisms of action (MOAs) by phenotypic screening with AI-powered image analysis, announced a research milestone in its collaboration with Takeda.

Anima Biotech identifies small molecule drug candidates that selectively modify the translation of mRNA into proteins on ribosomes to modulate the levels of protein produced, to consequently elucidate their MOA in a target space. Research of the company is powered by a custom technology that attaches fluorescent tags to frequently repeating transfer RNA (tRNA) pairs during translation with fluorescent light. One of Anima’s key areas of interest is neurosciences, the subject of an ongoing, up-to-$1.49 billion collaboration with Eli Lilly.

Top AI in Pharma & Healthcare Conferences in 2022 You Can’t Miss

   30952
Top AI in Pharma & Healthcare Conferences in 2022 You Can’t Miss

(Last updated: 27/07/2022) -- for sponsorships and media partnerships, reach out at info@biopharmatrend.com

Artificial intelligence (machine learning and deep learning, to be more specific) has become widely discussed topics in the area of life sciences and healthcare over the last several years and the excitement keeps growing. While a lot of pharmaceutical companies and healthcare organizations express considerable interest in possible new opportunities, associated with the use of artificial intelligence for early drug discovery, clinical trial optimization, and business intelligence, a considerable gap still exists when it comes to understanding new technologies by pharmaceutical professionals and leaders. The key questions here are these:

  • What machine learning / AI can and can’t do for the pharmaceutical industry

  • What should be done to harness practical and measurable value out of machine learning / AI?

  • How should it be done and what are the timelines for getting returns on investments?

7 Biotechs Fighting Rare Diseases With Gene-Editing Tech

   2321
7 Biotechs Fighting Rare Diseases With Gene-Editing Tech

As of now, only 5% of so-called rare diseases (orphan diseases) have an FDA-approved treatment available to patients. Rare diseases are defined as those affecting fewer than 1 in 200.000 people with almost 80% of all rare diseases being of genetic nature.

With recent progress in gene-editing technologies, including breakthroughs like CRISPR/Cas9 and new therapy delivery technologies, there is a wave of innovative biotech companies entering the field of rare diseases equipped with new ways to address the problem. 

In this article, we would like to outline a list of notable companies targeting rare diseases with cutting-edge gene therapies.  

 

9 Notable AI-powered Biotech Companies Founded in 2021

   1907
9 Notable AI-powered Biotech Companies Founded in 2021

Ever since the early 2000s, Artificial Intelligence (AI) has become a useful tool in various fields, from game design and speech recognition to powering driving cars and military applications. No wonder that big pharma companies are striving to keep up with technological progress and implementing AI in their internal R&D and business workflows. Pharmaceutical giants are actively recruiting machine learning and AI experts: for instance, from January 2020 to June 2021 AstraZeneca had 676 job vacancies for AI tech specialists, being followed by Johnson & Johnson and Takeda Pharmaceuticals with 616 and 545 positions respectively. Another source of technological and artificial intelligence expertise comes from external vendors by collaborating with AI-powered startups and more established companies. The cumulative number of such collaborations has increased significantly over the 2016-2021 timeframe, from 29 to 266, and continues to grow. For instance, in 2022 Merck launched a collaboration with Absci Corporation in order to produce enzymes tailored to Merck’s biomanufacturing applications with help of artificial intelligence, and Janssen partnered with a French startup Aquemia aiming to predict the potency of small molecules for a given target based on quantum physics-based calculations for datasets selected by Janssen.